Abstract
A Phase 3, Open-Label, Multicenter Study To Evaluate Eculizumab In Adolescents With Refractory Generalized Myasthenia Gravis (S5.009)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have